dekenor 25 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - deksketoprofēns - apvalkotā tablete - 25 mg
dolmen 25 mg granulas paciņā
menarini international operations luxembourg s.a., luxembourg - deksketoprofēns - granulas paciņā - 25 mg
dolmen 25 mg granulas paciņā
menarini international operations luxembourg s.a., luxembourg - deksketoprofēns - granulas paciņā - 25 mg
fenodex 12,5 mg apvalkotās tabletes
medochemie ltd., cyprus - deksketoprofēns - apvalkotā tablete - 12,5 mg
fenodex 25 mg apvalkotās tabletes
medochemie ltd., cyprus - deksketoprofēns - apvalkotā tablete - 25 mg
fenodex 12,5 mg apvalkotās tabletes
medochemie ltd., cyprus - deksketoprofēns - apvalkotā tablete - 12,5 mg
fenodex 25 mg apvalkotās tabletes
medochemie ltd., cyprus - deksketoprofēns - apvalkotā tablete - 25 mg
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiski līdzekļi - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.